PMN
ProMIS Neurosciences, Inc.9.34
+0.32+3.55%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
20.10MP/E (TTM)
-Basic EPS (TTM)
-20.00Dividend Yield
0%Recent Filings
8-K
Full-year loss, trial enrolled
ProMIS Neurosciences reported a $39.7M net loss for 2025, with R&D expenses surging to $33.4M from PRECISE-AD Phase 1b trial enrollment of 144 patients, completed December 2025. PMN310 showed no treatment-related SAEs. February 2026's $75.5M financing extends cash runway through 2027. Six-month interim data due early Q3 2026.
10-K
FY2025 results
ProMIS Neurosciences posted FY2025 operating losses of $40.2 million, up sharply from $16.8 million in FY2024, driven by $33.4 million in R&D spend—primarily $30.2 million on the PMN310 Phase 1b PRECISE-AD trial in early Alzheimer's, which completed enrollment of 144 patients by December 2025 with no serious adverse events to date. Q4 R&D costs accelerated amid trial momentum, while G&A held steady at $6.8 million despite severance. Cash burn hit $28.1 million annually, ending FY2025 at $6.1 million after $21 million from warrant exercises and offerings, but January 2026's $75.5 million PIPE bolsters runway through 2027. No revenue; net loss swung to $39.7 million from prior-year $2.8 million profit on warrant gains. Clinical delays loom large.
8-K
$75M PIPE funds PMN310
ProMIS Neurosciences signed a $75M PIPE deal on January 29, 2026, issuing 6.8M common shares and warrants for 7M more shares at $14.40 strike, closing February 3. Insiders bought at a premium while others paid $10.77 per share. Funds extend runway into 2028. Warrants expire post-PMN310 data readout.
8-K
Nasdaq compliance regained
ProMIS Neurosciences regained Nasdaq Capital Market listing compliance on December 12, 2025, after its common shares traded at $1.00 or higher for 10 straight business days from November 28 to December 11. This resolves a bid price deficiency first flagged January 8, 2025, extended to December 29 via grace period. Compliance secured. No delisting risk remains.
8-K
1-for-25 reverse split effective
ProMIS Neurosciences filed articles of amendment on November 24, 2025, to execute a one-for-25 reverse stock split, effective 12:01 a.m. ET November 28, slashing outstanding common shares from ~53.8M to ~2.2M. Approved by shareholders on November 17 and board same day, it targets Nasdaq's $1 bid price deficiency after a compliance extension to December 29. Split-adjusted trading starts November 28 under PMN. Cash replaces fractions.
IPO
Employees
Sector
Industry
ACIU
AC Immune SA
3.29+0.05
ALEC
Alector, Inc.
1.39-0.03
ALZN
Alzamend Neuro, Inc.
2.16+0.05
ANVS
Annovis Bio, Inc.
3.93+0.15
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
OABI
OmniAb, Inc.
2.05+0.02
PMVP
PMV Pharmaceuticals, Inc.
1.18-0.02
PRME
Prime Medicine, Inc.
3.88-0.16
PRTA
Prothena Corporation plc
9.75-0.22